Verici Dx (FRA:63V) Retained Earnings: €-39.30 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Verici Dx Retained Earnings?

Verici Dx FRA:63V -20.00% Retained Earnings is €-39.30 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Verici Dx's retained earnings for the quarter that ended in Dec. 2025 was €-39.30 Mil.

Verici Dx's quarterly retained earnings increased from Dec. 2024 (€-37.32 Mil) to Jun. 2025 (€-36.56 Mil) but then declined from Jun. 2025 (€-36.56 Mil) to Dec. 2025 (€-39.30 Mil).

Verici Dx's annual retained earnings declined from Dec. 2023 (€-30.45 Mil) to Dec. 2024 (€-37.32 Mil) and declined from Dec. 2024 (€-37.32 Mil) to Dec. 2025 (€-39.30 Mil).


Verici Dx  (FRA:63V) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Verici Dx Retained Earnings Historical Data

* Premium members only.

The historical data trend for Verici Dx's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Verici Dx Retained Earnings Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial -11.56 -23.10 -30.45 -37.32 -39.30

Verici Dx Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -30.45 -32.10 -37.32 -36.56 -39.30

Verici Dx Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-39.30 Mil mean?
Verici Dx (FRA:63V) has a Retained Earnings of €-39.30 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Verici Dx and its competitors.
Is Verici Dx's Retained Earnings too high?
Verici Dx's current Retained Earnings is €-39.30 Mil.
How does Verici Dx's Retained Earnings compare to TMO and DHR?
Verici Dx's Retained Earnings of €-39.30 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Diagnostics & Research company?
A good Retained Earnings depends on the Medical Diagnostics & Research industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Verici Dx and its competitors. Verici Dx's current Retained Earnings is €-39.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (FRA:63V) has a current Retained Earnings of €-39.30 Mil. The current Retained Earnings is €-39.30 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Verici Dx (FRA:63V), the current Retained Earnings is €-39.30 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Verici Dx Business Description

Other Exchanges VRCI:UK
Address 19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.